Print

News

  • Global regulators and coalition of pharma and vaccine manufacturing associations come together to discuss COVID-19 pandemic response (July 2021)

    On 7 July 2021, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a (virtual) workshop titled ‘Enabling Manufacturing Capacity in the COVID-19 Pandemic’ with representatives from the leading association bodies representing biotech firms, developing and industrialized countries vaccine Read More
  • IGBA Launches a Whitepaper: a Vision for the Global Generic and Biosimilar Medicines Industry (July 2021)

    Today the International Generic and Biosimilar Medicines Association (IGBA) is launching a whitepaper: A Vision for the Global Generic and Biosimilar Medicines Industry, which covers the strong contribution of this pharmaceutical sector to global health outcomes and economies, the opportunities, Read More
  • IGBA Applauds UK MHRA Biosimilar Guidance Revision: Science-driven Evolution for Sustainable Access to Biologics (May 2021)

    The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, welcomes the UK MHRA publication of its updated guidance on the licensing of biosimilar products (10 May 2021). This publication marks a positive Read More
  • The WHO Global Diabetes Compact: an opportunity for lasting change (April 2021)

    13 April 2021 - The Global Diabetes Compact is a major new WHO initiative which will unite people working in diabetes prevention, treatment and care, including people living with the condition, around a common agenda.  Read More
  • Sudarshan Jain takes over the position of IGBA Chair (January 2021)

    Geneva, 11 January 2021 - IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), is taking over the position of Read More
  • IGBA Launches First Global Biosimilars Week (November 2020)

    Geneva, November 16, 2020 – Today the International Generic and Biosimilar Medicines Association (IGBA) launched the first ever Global Biosimilars Week, which is aimed at raising the awareness of biosimilar medicines worldwide through a globally aligned educational initiative. Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11

Print

Vision and Mission

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.

Print

The IGBA

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).

Annual Conference - Warsaw 2019

Annual Conference - Budapest 2018

Annual Conference - Lisboa 2017

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)2 5346607 (S. Kox)
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site